Evaluation of the synergistic antifungal activity of micafungin and voriconazole plus sertraline against Candida auris

[1]  N. Jauregizar,et al.  In Vitro Synergistic Interactions of Isavuconazole and Echinocandins against Candida auris , 2021, Antibiotics.

[2]  M. Castanheira,et al.  Evaluation of Synergistic Activity of Isavuconazole or Voriconazole plus Anidulafungin and the Occurrence and Genetic Characterization of Candida auris Detected in a Surveillance Program , 2021, Antimicrobial Agents and Chemotherapy.

[3]  G. Torre-Amione,et al.  Outbreak of Candida auris infection in a COVID-19 hospital in Mexico , 2021, Clinical Microbiology and Infection.

[4]  Muluneh Worku,et al.  Candida auris: From Multidrug Resistance to Pan-Resistant Strains , 2020, Infection and drug resistance.

[5]  E. Berkow,et al.  Candida auris Isolates Resistant to Three Classes of Antifungal Medications — New York, 2019 , 2020, MMWR. Morbidity and mortality weekly report.

[6]  B. O’Brien,et al.  In Vitro Evaluation of Antifungal Drug Combinations against Multidrug-Resistant Candida auris Isolates from New York Outbreak , 2019, Antimicrobial Agents and Chemotherapy.

[7]  M. Martínez-Reséndez,et al.  Evaluation of the expanding spectrum of sertraline against uncommon fungal pathogens. , 2020, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.

[8]  J. Jeyakanthan,et al.  Sertraline as a promising antifungal agent: inhibition of growth and biofilm of Candida auris with special focus on the mechanism of action in vitro , 2020, Journal of applied microbiology.

[9]  M. Fisher,et al.  Global epidemiology of emerging Candida auris. , 2019, Current opinion in microbiology.

[10]  A. Coste,et al.  Review on Antifungal Resistance Mechanisms in the Emerging Pathogen Candida auris , 2019, Front. Microbiol..

[11]  Antibiotic resistance threats in the United States, 2019 , 2019 .

[12]  S. Lockhart.  Candida auris and multidrug resistance: defining the new normal. , 2019, Fungal genetics and biology : FG & B.

[13]  E. Tartari,et al.  Control of Candida auris in healthcare institutions: Outcome of an International Society for Antimicrobial Chemotherapy expert meeting , 2019, International Journal of Antimicrobial Agents.

[14]  H. Badali,et al.  In Vitro Interaction of Geldanamycin with Triazoles and Echinocandins Against Common and Emerging Candida Species , 2019, Mycopathologia.

[15]  B. Wickes,et al.  Development of High-Level Echinocandin Resistance in a Patient With Recurrent Candida auris Candidemia Secondary to Chronic Candiduria , 2019, Open forum infectious diseases.

[16]  G. González,et al.  In vivo evaluation of the antifungal activity of sertraline against Aspergillus fumigatus , 2018, The Journal of antimicrobial chemotherapy.

[17]  J. Lopez-Ribot,et al.  Screening a Repurposing Library for Inhibitors of Multidrug-Resistant Candida auris Identifies Ebselen as a Repositionable Candidate for Antifungal Drug Development , 2018, Antimicrobial Agents and Chemotherapy.

[18]  H. Badali,et al.  In Vitro Interactions of Echinocandins with Triazoles against Multidrug-Resistant Candida auris , 2017, Antimicrobial Agents and Chemotherapy.

[19]  P. Chandrasekar,et al.  Candida auris: a worrisome, globally emerging pathogen , 2017, Expert review of anti-infective therapy.

[20]  Shukla Das,et al.  Candida auris candidaemia in Indian ICUs: analysis of risk factors , 2017, The Journal of antimicrobial chemotherapy.

[21]  Christina A. Cuomo,et al.  Simultaneous Emergence of Multidrug-Resistant Candida auris on 3 Continents Confirmed by Whole-Genome Sequencing and Epidemiological Analyses , 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[22]  D. Boulware,et al.  Efficacy of Adjunctive Sertraline for the Treatment of HIV-Associated Cryptococcal Meningitis: an open-label dose-ranging study , 2016, The Lancet. Infectious diseases.

[23]  M. Ghannoum,et al.  Multilaboratory Testing of Antifungal Drug Combinations against Candida Species and Aspergillus fumigatus: Utility of 100 Percent Inhibition as the Endpoint , 2014, Antimicrobial Agents and Chemotherapy.

[24]  A. Chowdhary,et al.  Multidrug-resistant endemic clonal strain of Candida auris in India , 2014, European Journal of Clinical Microbiology & Infectious Diseases.

[25]  M. Sachs,et al.  The Antidepressant Sertraline Provides a Promising Therapeutic Option for Neurotropic Cryptococcal Infections , 2012, Antimicrobial Agents and Chemotherapy.

[26]  H. Yamaguchi,et al.  Candida auris sp. nov., a novel ascomycetous yeast isolated from the external ear canal of an inpatient in a Japanese hospital , 2009, Microbiology and immunology.

[27]  L. Fornecker,et al.  Antifungal combination treatment: a future perspective. , 2006, International journal of antimicrobial agents.

[28]  M. Ghannoum,et al.  Combination Treatment of Invasive Fungal Infections , 2005, Clinical Microbiology Reviews.

[29]  F. Odds,et al.  Synergy, antagonism, and what the chequerboard puts between them. , 2003, The Journal of antimicrobial chemotherapy.

[30]  J. Peter,et al.  Testing Conditions for Determination of Minimum Fungicidal Concentrations of New and Established Antifungal Agents for Aspergillus spp.: NCCLS Collaborative Study , 2002, Journal of Clinical Microbiology.

[31]  W. J. Novick.  Development of in vitro susceptibility testing criteria and quality control parameters , 1989 .